

# Botanix Pharmaceuticals Ltd

## (BOT \$0.059) Speculative Buy

EUROZ HARTLEYS

Analyst	Date	Price Target
Seth Lizee	March 2022	\$0.17/sh

### December Quarter: Big Year Ahead!

#### Event

BOT has released their December quarterly update. The company continues to make solid progress on its various clinical programs, with 2022 shaping up to be a pivotal year for the company.

#### Key points

Key updates from the quarterly:

- BTX1702 (Rosacea) phase 1b/2a study on track to complete enrolments in mid-2022;
- BTX1204A (Atopic dermatitis) proof of concept study on track to complete enrolment this quarter, with data expected 2Q CY22;
- BTX1801 (Antimicrobial) phase 2b study on track to initiate late this quarter
- BOT continues to explore new avenues to leverage the Permetrex<sup>TM</sup> platform, as well as other business development opportunities
- The company remains well funded, finishing the quarter with \$16.8m, the company additionally anticipating receipt of its R&D tax return this quarter

#### Action

#### Speculative Buy, \$0.17/sh

Botanix Pharmaceuticals Ltd is a clinical stage synthetic cannabinoid (CBD) pharmaceutical company.

The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge. We believe the market is pricing in failure, or very close to it, whereas our analysis into the company's programs and respective clinical studies suggest the opposite.

We believe the stock will trade up as the market begins to better understand the potential of BOT's programs, we anticipate this will occur as we near the multiple catalyst due in coming months. If BOT can deliver successful clinical outcomes, we believe the stock can trade above our price target, potentially multiples of it.

#### Key Catalysts

- BTX1801 (Antimicrobial) phase 2b kick off - late Q1 CY22
- BTX1204A (Atopic Dermatitis) Proof of concept results- Early Q2 CY22
- BTX1702 (Rosacea) phase 1b/2a results - Mid 2022
- BTX1503 (Acne) - ongoing updates relating to planning of phase 3 clinical studies (informed by successful completion of BTX1702 phase 1b/2a study)
- Updates relating to new indications, Permetrex<sup>TM</sup> opportunities, and business development activities

Botanix Pharmaceuticals	Year end 30 June	
Share Price	0.059	A\$/sh
Price Target	0.17	A\$/sh
Valuation	0.17	A\$/sh
Shares on issue	1041.6m, diluted	
Market Capitalisation	61.5	A\$m
Enterprise Value	37.6	A\$m
Debt (Jun'21)	0.0	A\$m
Cash (Jun'21)	16.8	A\$m
Unpaid cap	7.1	A\$m
Turnover	5.2m	sh/day
12 Mth Hi-Lo	0.045-0.19	A\$/sh
Balance date	June 30th	

#### Directors & Management

Vince Ippolito	Executive Chair & President
Matthew Callahan	Executive Director
Dr William Bosch	Executive Director / CSO
Dr Stewart Washer	Executive Director
Dr Clarence Young	Chief Medical Officer
Anthony Robinson	VP of Development
Lynda Berne	Head of Commercial


#### Company Details

Level 1, 50 Angove Street,  
North Perth WA 6006, Australia  
3602 Horizon Drive, Suite 160,  
King of Prussia, PA 19406, USA

AU +61 8 6555 2945  
US +1 445 300 3403

botanixpharma.com

#### Share Price Chart



## Copyright & Distribution

The material contained in this communication (and all attachments) is prepared for the exclusive use of clients of Euroz Hartleys Limited (ACN 104 195 057) only.

Euroz Hartleys Limited is the holder of an Australian Financial Services Licence (AFSL 230052) and is a participant of the Australian Securities Exchange Group, Cboe and NSX.

The information contained herein is confidential. If you are not the intended recipient no confidentiality is lost by your receipt of it. Please delete and destroy all copies, and contact Euroz Hartleys Limited on (+618) 9488 1400. You should not use, copy, disclose or distribute this information without the express written authority of Euroz Hartleys Limited.

## Disclaimer & Disclosure

Euroz Hartleys Limited, and their associates declare that they deal in securities as part of their securities business and consequently may have an interest in the securities recommended herein (if any). This may include providing equity capital market services to the issuing company, hold a position in the securities, trading as principal or agent and as such may effect transactions not consistent with the recommendation (if any) in this report.

Euroz Hartleys Limited declares that they may have separately or jointly acted as an underwriter, arranger, co-arranger or adviser in equity capital raisings, and will have received a fee for its services, from or any company mentioned within this report during the last 12 months.

You should not act on any recommendation issued by Euroz Hartleys Limited without first consulting your investment adviser in order to ascertain whether the recommendation (if any) is appropriate, having regard to your objectives, financial situation and needs. Nothing in this report shall be construed as a solicitation to buy or sell a security, or to engage in or refrain from engaging in any transaction.

Euroz Hartleys Limited believes that the information and advice contained herein is correct at the time of compilation, however we make no representation or warranty that it is accurate, complete, reliable or up to date, nor do we accept any obligation to correct or update the opinions in it. The opinions expressed are subject to change without notice. No member of Euroz Hartleys Limited accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this material.

We cannot guarantee that the integrity of this communication has been maintained, is free from errors, virus interception or interference.

The author of this publication, Euroz Hartleys Limited, its directors and their associates from time to time may hold shares in the security/securities mentioned in this Research document and therefore may benefit from any increase in the price of those securities. Euroz Hartleys Limited, and its Advisers may earn brokerage, fees, commissions, other benefits or advantages as a result of transactions arising from any advice mentioned in publications to clients.

To view the Industrials Disclaimers, please visit the below link:

<https://www.eurozhartleys.com/wp-content/uploads/Industrials-Disclaimers-March-22.pdf>

## Analyst Certification

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities, and we are not in possession of, nor does this Research contain any inside information.

No part of our compensation was, is or will be directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in this research, nor has any attempt been made to influence this Research.

## Contact Details

**Euroz Hartleys Limited** +61 8 9488 1400

### Research Analysts

Jon Bishop - Head of Research	+61 8 9488 1481
Mike Millikan - Resources Analyst	+61 8 9268 2805
Kyle De Souza - Resources Analyst	+61 8 9488 1427
Michael Scantlebury - Resources Analyst	+61 8 9268 2837
Steven Clark - Resources Analyst	+61 8 9488 1430
Trent Barnett - Senior Analyst	+61 8 9268 3052
Gavin Allen - Senior Analyst	+61 8 9488 1413
Harry Stevenson - Industrials Analyst	+61 8 9488 1429
Seth Lizee - Research Analyst	+61 8 9488 1414

---

### Euroz Hartleys Limited

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of Euroz Hartleys Limited or any member or employee thereof. Refer to full disclaimer at the end of this document.

---